Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H2 2016, provides an overview of the Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever (Lassa Hemorrhagic Fever) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Lassa Fever (Lassa Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Arno Therapeutics Inc
Celgene Corp
Etubics Corp
Kineta Inc
Profectus BioSciences Inc
SIGA Technologies Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Lassa Fever (Lassa Hemorrhagic Fever) Overview 7
Therapeutics Development 8
Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Overview 8
Pipeline Products for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis 9
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Development by Companies 10
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics under Investigation by Universities/Institutes 11
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Products Glance 12
Early Stage Products 12
Lassa Fever (Lassa Hemorrhagic Fever) - Products under Development by Companies 13
Lassa Fever (Lassa Hemorrhagic Fever) - Products under Investigation by Universities/Institutes 14
Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development 15
Arno Therapeutics Inc 15
Celgene Corp 16
Etubics Corp 17
Kineta Inc 18
Profectus BioSciences Inc 19
SIGA Technologies Inc 20
Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AR-12 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
CC-11050 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
DEF-201 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
FBH-003 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
KIN-1400 - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
lassa fever vaccine - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
lassa fever vaccine - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
lassa fever vaccine - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
LHF-535 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
ML-29 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibodies for Lassa Fever - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Monoclonal Antibodies for Viral Infections - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules for Lassa Fever - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
ST-193 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects 50
Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones 51
Featured News & Press Releases 51
May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials 51
Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals 51
May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54
List of Tables
Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2016 8
Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Arno Therapeutics Inc, H2 2016 15
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Celgene Corp, H2 2016 16
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2016 17
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2016 18
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2016 19
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by SIGA Technologies Inc, H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H2 2016 50
List of Figures
Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2016 8
Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever) - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Top 10 Targets, H2 2016 22
Number of Products by Stage and Top 10 Targets, H2 2016 22
Number of Products by Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28
